HER2-positive Breast Cancer Registry
This is an observational study, meaning researchers will collect information about people with HER2-positive breast cancer to better understand the disease. There are no specific interventions (treatments) being tested. The study aims to enroll 1000 participants and is open to adults aged 18 and older, of all genders, who have Stage I-IV HER2-positive breast cancer. The main goal is to look at how long people live after diagnosis, up to 5 years. This will help researchers understand how patient or tumor characteristics might be linked to outcomes in HER2-positive breast cancer. The current recruitment status is unclear.
- Study design
- This is an observational study, not testing a specific treatment, and plans to include 1000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' overall survival rate will be measured from diagnosis to 5 years after diagnosis.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HER2-positive Breast Cancer Registry
At a glance
Conditions
Where it's being run
6 sites across 2 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Overall survival rateFrom diagnosis to 5 years after diagnosis
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.